Compare Biocon Ltd with ALEMBIC LTD - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON vs ALEMBIC LTD - Comparison Results

BIOCON      Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

ALEMBIC LTD 
   Change

Alembic Limited, in its 99 years of existence, has evolved from being a tincture manufacturer to one of the prominent indigenous pharma companies in India. It is among the top players in the macrolides (anti-infective) and anti-microbials (animal hea... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON ALEMBIC LTD BIOCON /
ALEMBIC LTD
 
P/E (TTM) x 31.1 56.2 55.4% View Chart
P/BV x 4.0 4.8 82.8% View Chart
Dividend Yield % 0.2 0.2 116.4%  

Financials

 BIOCON    ALEMBIC LTD
EQUITY SHARE DATA
    BIOCON
Mar-19
ALEMBIC LTD
Mar-18
BIOCON /
ALEMBIC LTD
5-Yr Chart
Click to enlarge
High Rs70772 982.4%   
Low Rs55434 1,633.6%   
Sales per share (Unadj.) Rs91.94.7 1,955.2%  
Earnings per share (Unadj.) Rs16.76.1 273.8%  
Cash flow per share (Unadj.) Rs24.26.2 387.1%  
Dividends per share (Unadj.) Rs1.000.20 500.0%  
Dividend yield (eoy) %0.20.4 42.0%  
Book value per share (Unadj.) Rs101.640.7 250.0%  
Shares outstanding (eoy) m600.00267.03 224.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x6.911.3 60.9%   
Avg P/E ratio x37.78.7 435.0%  
P/CF ratio (eoy) x26.18.5 307.7%  
Price / Book Value ratio x6.21.3 476.4%  
Dividend payout %6.03.3 182.6%   
Avg Mkt Cap Rs m378,33014,139 2,675.7%   
No. of employees `0006.1NA-   
Total wages/salary Rs m11,653207 5,618.6%   
Avg. sales/employee Rs Th8,994.3NM-  
Avg. wages/employee Rs Th1,900.7NM-  
Avg. net profit/employee Rs Th1,635.3NM-  
INCOME DATA
Net Sales Rs m55,1441,255 4,393.2%  
Other income Rs m1,444370 390.1%   
Total revenues Rs m56,5881,625 3,481.5%   
Gross profit Rs m15,883111 14,296.1%  
Depreciation Rs m4,47838 11,846.6%   
Interest Rs m7092 41,705.9%   
Profit before tax Rs m12,140442 2,747.8%   
Minority Interest Rs m90-   
Prior Period Items Rs m01,212 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,12324 8,864.3%   
Profit after tax Rs m10,0261,630 615.1%  
Gross profit margin %28.88.9 325.4%  
Effective tax rate %17.55.4 322.6%   
Net profit margin %18.2129.8 14.0%  
BALANCE SHEET DATA
Current assets Rs m48,2281,867 2,583.0%   
Current liabilities Rs m30,376591 5,138.0%   
Net working cap to sales %32.4101.6 31.8%  
Current ratio x1.63.2 50.3%  
Inventory Days Days6894 72.5%  
Debtors Days Days8674 116.3%  
Net fixed assets Rs m64,1301,791 3,580.9%   
Share capital Rs m3,000534 561.7%   
"Free" reserves Rs m57,98010,324 561.6%   
Net worth Rs m60,98010,858 561.6%   
Long term debt Rs m15,76641 38,267.0%   
Total assets Rs m121,92411,591 1,051.9%  
Interest coverage x18.1260.9 6.9%   
Debt to equity ratio x0.30 6,813.6%  
Sales to assets ratio x0.50.1 417.6%   
Return on assets %8.814.1 62.5%  
Return on equity %16.415.0 109.5%  
Return on capital %16.815.2 110.3%  
Exports to sales %28.11.5 1,819.3%   
Imports to sales %18.921.0 89.9%   
Exports (fob) Rs m15,50619 79,927.8%   
Imports (cif) Rs m10,399263 3,948.9%   
Fx inflow Rs m15,50619 79,927.8%   
Fx outflow Rs m10,399264 3,941.7%   
Net fx Rs m5,107-244 -2,089.4%   
CASH FLOW
From Operations Rs m11,546236 4,896.5%  
From Investments Rs m-7,138-224 3,186.6%  
From Financial Activity Rs m-2,417-27 9,086.5%  
Net Cashflow Rs m2,103-15 -14,209.5%  

Share Holding

Indian Promoters % 40.4 64.0 63.1%  
Foreign collaborators % 20.6 0.0 -  
Indian inst/Mut Fund % 8.4 0.2 4,200.0%  
FIIs % 10.7 9.7 110.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 26.1 76.2%  
Shareholders   109,995 54,701 201.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON With:   SUN PHARMA  DR. REDDYS LAB  NOVARTIS  FULFORD INDIA  PROCTER & GAMBLE HEALTH  

Compare BIOCON With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades in Green; RBI Keeps Repo Rate Unchanged at 4%(12:30 pm)

Share markets in India are presently trading on a positive note, after the RBI kept repo rate unchanged at 4%.

Related Views on News

BIOCON Announces Quarterly Results (3QFY20); Net Profit Up 1.2% (Quarterly Result Update)

Jan 24, 2020 | Updated on Jan 24, 2020

For the quarter ended December 2019, BIOCON has posted a net profit of Rs 2 bn (up 1.2% YoY). Sales on the other hand came in at Rs 17 bn (up 13.5% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

BIOCON Announces Quarterly Results (2QFY20); Net Profit Down 30.5% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, BIOCON has posted a net profit of Rs 3 bn (down 30.5% YoY). Sales on the other hand came in at Rs 16 bn (up 19.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

ALEMBIC LTD Announces Quarterly Results (1QFY20); Net Profit Down 70.9% (Quarterly Result Update)

Aug 27, 2019 | Updated on Aug 27, 2019

For the quarter ended June 2019, ALEMBIC LTD has posted a net profit of Rs 20 m (down 70.9% YoY). Sales on the other hand came in at Rs 260 m (down 41.5% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

BIOCON Announces Quarterly Results (1QFY20); Net Profit Down 11.5% (Quarterly Result Update)

Jul 29, 2019 | Updated on Jul 29, 2019

For the quarter ended June 2019, BIOCON has posted a net profit of Rs 1 bn (down 11.5% YoY). Sales on the other hand came in at Rs 5 bn (down 57.2% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

ALEMBIC LTD Announces Quarterly Results (4QFY19); Net Profit Down 14.6% (Quarterly Result Update)

May 17, 2019 | Updated on May 17, 2019

For the quarter ended March 2019, ALEMBIC LTD has posted a net profit of Rs 40 m (down 14.6% YoY). Sales on the other hand came in at Rs 253 m (down 23.8% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

More Views on News

Most Popular

These 5 Smallcaps Deserve a Place in Your Coffee Can Portfolio(Profit Hunter)

Jul 28, 2020

When it comes to quality stocks, doing less is more.

Before You Buy Your First Electric Vehicle Consider Buying this Stock(Profit Hunter)

Jul 29, 2020

As competition intensifies in the electric vehicle space, only few will create huge wealth over the years.

Gold or Silver: Which One Should You Buy Now?(Fast Profits Daily)

Jul 24, 2020

Silver and gold are both vying for your attention. Which is the better trade today?

A Zero Loss Strategy that Also Maximizes Returns in Volatile Stock Markets(Views On News)

Jul 24, 2020

Here's how to never lose money in stock markets.

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

BIOCON SHARE PRICE


Aug 6, 2020 03:33 PM

TRACK BIOCON

BIOCON - IPCA LABS COMPARISON

COMPARE BIOCON WITH

MARKET STATS